123
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Drug Discovery for Neglected Diseases: Molecular Target-Based and Phenotypic Approaches : Miniperspectives Series on Phenotypic Screening for Antiinfective Targets

      review-article
      Journal of Medicinal Chemistry
      American Chemical Society

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Drug discovery for neglected tropical diseases is carried out using both target-based and phenotypic approaches. In this paper, target-based approaches are discussed, with a particular focus on human African trypanosomiasis. Target-based drug discovery can be successful, but careful selection of targets is required. There are still very few fully validated drug targets in neglected diseases, and there is a high attrition rate in target-based drug discovery for these diseases. Phenotypic screening is a powerful method in both neglected and non-neglected diseases and has been very successfully used. Identification of molecular targets from phenotypic approaches can be a way to identify potential new drug targets.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.

          Miltefosine is an alkylphosphocholine drug with demonstrated activity against various parasite species and cancer cells as well as some pathogenic bacteria and fungi. For 10 years it has been licensed in India for the treatment of visceral leishmaniasis (VL), a fatal neglected parasitic disease. It is the first and still the only oral drug that can be used to treat VL and cutaneous leishmaniasis (CL). The standard 28 day miltefosine monotherapy regimen is well tolerated, except for mild gastrointestinal side effects, although its teratogenic potential severely hampers its general use in the clinic and roll-out in national elimination programmes. The pharmacokinetics of miltefosine are mainly characterized by its long residence time in the body, resulting in extensive drug accumulation during treatment and long elimination half-lives. At the moment, different combination therapy strategies encompassing miltefosine are being tested in multiple controlled clinical trials in various geographical areas of endemicity, both in South Asia and East Africa. We here review the most salient pre-clinical and clinical pharmacological aspects of miltefosine, its mechanism of action against Leishmania parasites and other pathogens, and provide a systematic overview of the efficacy and safety data from all clinical trials of miltefosine, either alone or in combination, in the treatment of VL and CL.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases

            To enable the establishment of a drug discovery operation for neglected diseases, out of 2.3 million commercially available compounds 222 552 compounds were selected for an in silico library, 57 438 for a diverse general screening library, and 1 697 compounds for a focused kinase set. Compiling these libraries required a robust strategy for compound selection. Rules for unwanted groups were defined and selection criteria to enrich for lead-like compounds which facilitate straightforward structure–activity relationship exploration were established. Further, a literature and patent review was undertaken to extract key recognition elements of kinase inhibitors (“core fragments”) to assemble a focused library for hit discovery for kinases. Computational and experimental characterisation of the general screening library revealed that the selected compounds 1) span a broad range of lead-like space, 2) show a high degree of structural integrity and purity, and 3) demonstrate appropriate solubility for the purposes of biochemical screening. The implications of this study for compound selection, especially in an academic environment with limited resources, are considered.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.

                Bookmark

                Author and article information

                Journal
                J Med Chem
                J. Med. Chem
                jm
                jmcmar
                Journal of Medicinal Chemistry
                American Chemical Society
                0022-2623
                1520-4804
                09 September 2013
                24 October 2013
                : 56
                : 20 , Miniperspectives Series on Phenotypic Screening for Antiinfective Targets
                : 7719-7726
                Affiliations
                [1]Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee , Dundee DD1 5EH, U.K.
                Author notes
                [* ]Phone: +44 1382 386 240. E-mail: i.h.gilbert@ 123456dundee.ac.uk .
                Article
                10.1021/jm400362b
                3954685
                24015767
                29cd8ba9-fa0d-40dd-83a9-55b63cdf739e
                Copyright © 2013 American Chemical Society
                History
                : 11 March 2013
                Categories
                Perspective
                Custom metadata
                jm400362b
                jm-2013-00362b

                Pharmaceutical chemistry
                Pharmaceutical chemistry

                Comments

                Comment on this article